Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Curosurf. Always confirm against the full prescribing information.
70 interactions
Ceritinib
Poractant alfa may increase the bradycardic activities of Ceritinib.
Level 1 evidence
Crizotinib
Crizotinib may increase the bradycardic activities of Poractant alfa.
Level 1 evidence
Fexinidazole
The risk or severity of adverse effects can be increased when Poractant alfa is combined with Fexinidazole.
Level 1 evidence
Octreotide
The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Poractant alfa.
Level 1 evidence
Ruxolitinib
Ruxolitinib may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Acebutolol
Acebutolol may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Alfentanil
Alfentanil may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Amiodarone
Amiodarone may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Amlodipine
Amlodipine may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Atenolol
Atenolol may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Bendroflumethiazide
Bendroflumethiazide may increase the bradycardic activities of Poractant alfa.
Level 2 evidence
Benzgalantamine
Poractant alfa may increase the bradycardic activities of Benzgalantamine.
Level 2 evidence
Enter your NPI to unlock 1 major interaction for Curosurf
Curosurf (Poractant Alfa) has 70 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Curosurf (Poractant Alfa) has 1 major, 5 moderate, and 64 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Curosurf. Always confirm against the full prescribing information.